albumin-bound paclitaxel / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 274 Diseases   1060 Trials   1060 Trials   12189 News 


«12345678910111213...178179»
  • ||||||||||  gemcitabine / Generic mfg.
    Clinical, Retrospective data, Review, Journal, Combination therapy, Monotherapy, Metastases:  Efficacy of first-line combination therapies versus gemcitabine monotherapy for advanced pancreatic cancer: a systematic review and network meta-analysis. (Pubmed Central) -  Aug 8, 2024   
    The analysis revealed that gemcitabine+nab-paclitaxel (GA), GA with platinum and fluorouracil (GA+Plat+FU), gemcitabine with fluorouracil (G+FU), G+Plt+FU, and FOLFIRINOX were associated with superior OS and PFS compared to gemcitabine monotherapy...These findings support the use of gemcitabine-based or fluorouracil-based triplet or quadruplet regimens for better survival outcomes in patients with advanced pancreatic cancer. Further research is warranted to explore the potential benefits of adding chemotherapy agents, such as fluorouracil, to the GA doublet regimen.
  • ||||||||||  pegylated liposomal doxorubicin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
    Review, Journal:  Chemoradiotherapy and nanomedicine: Drug mechanisms and delivery systems. (Pubmed Central) -  Aug 7, 2024   
    Though many challenges remain, the ongoing progress evidences a promising future for both nanomedicine and chemoradiotherapy. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Therapeutic Approaches and Drug Discovery > Nanomedicine for Cardiovascular Disease Therapeutic Approaches and Drug Discovery > Emerging Technologies.
  • ||||||||||  gemcitabine / Generic mfg.
    Journal:  Preoperative chemotherapy with Gemcitabine for pancreatic cancer causes zinc deficiency. (Pubmed Central) -  Aug 5, 2024   
    The preoperative chemotherapy consistently reduced the serum zinc concentrations in the PC patients, regardless of their regimen such as GEM + S1 and GEM + nab-PTX. Monitoring the serum zinc concentration and appropriate zinc supplementation may be essential for PC patients undergoing preoperative chemotherapy and pancreatectomy.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), vibostolimab/pembrolizumab (MK-7684A) / Merck (MSD)
    Enrollment closed, Trial completion date, Trial primary completion date, Pan tumor:  MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) (clinicaltrials.gov) -  Aug 1, 2024   
    P2,  N=610, Active, not recruiting, 
    The study commenced enrolment in September 2023, with preliminary findings regarding the primary endpoint anticipated by January 2025. Recruiting --> Active, not recruiting | Trial completion date: Feb 2027 --> Aug 2026 | Trial primary completion date: Feb 2027 --> Aug 2026
  • ||||||||||  Review, Journal:  New Frontiers in Pancreatic Cancer Management: Current Treatment Options and the Emerging Role of Neoadjuvant Therapy. (Pubmed Central) -  Jul 31, 2024   
    Recent advances in treatment protocols, such as FOLFIRINOX and gemcitabine-nab-paclitaxel, now integral to NAT strategies, have shown promising results in increasing the proportion of patients eligible for surgery by effectively reducing tumor size and addressing micrometastatic disease...Despite these advancements, the role of NAT continues to evolve, necessitating ongoing research to optimize treatment regimens, minimize adverse effects, and identify patient populations that would benefit most from these approaches. Through a detailed analysis of current literature and recent clinical trials, this review highlights the transformative potential of NAT in managing PDAC, especially in patients with borderline resectable or locally advanced stages, promising a shift towards more personalized and effective management strategies for PDAC.
  • ||||||||||  paricalcitol / Generic mfg., albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
    Trial completion date, Metastases:  Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer (clinicaltrials.gov) -  Jul 31, 2024   
    P1/2,  N=36, Active, not recruiting, 
    Trial completion date: Sep 2024 --> Jan 2025 Trial completion date: Jul 2024 --> Jan 2025
  • ||||||||||  ibrilatazar (ABTL0812) / Ability Pharma
    Trial completion date, Combination therapy, Metastases:  A Study of ABTL0812 in Pancreatic Cancer (clinicaltrials.gov) -  Jul 31, 2024   
    P1/2,  N=60, Suspended, 
    Trial completion date: Jul 2024 --> Jan 2025 Trial completion date: Apr 2024 --> Dec 2024
  • ||||||||||  albumin-bound paclitaxel / Generic mfg.
    Preclinical, Journal:  XRCC2 knockdown effectively sensitizes esophageal cancer to albumin-paclitaxel in vitro and in vivo. (Pubmed Central) -  Jul 26, 2024   
    In vivo, transfection of shXRCC2 with or without albumin-paclitaxel treatment both decreased the tumor size and weight, as well as the expression of XRCC2 and Ki-67 in xenografted mice. XRCC2 transcriptionally regulated by SP2 promoted proliferation, migration, invasion, and chemoresistance of EC cells.
  • ||||||||||  Orpathys (savolitinib) / AstraZeneca, Hutchmed
    Savolitinib and Third-Generation EGFR-TKI Therapy in EGFRm, MET-Altered NSCLC Patients: A Case Series (Exhibit Hall) -  Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2159;    
    After 20 months of gefitinib treatment, the patient developed a central nervous system progression...Fourth-line therapy with savolitinib and osimertinib resulted in partial response (PR) with 7-month PFS...Currently, the patient was receiving albumin-paclitaxel monotherapy (7th line)...A comprehensive test of MET should be conducted by various ways. Dual-targeted therapy may be effective in EGFRm and MET-altered patients.
  • ||||||||||  Tyvyt (sintilimab) / Eli Lilly
    Down-Stage To Thoracic Surgery after Neoadjuvant Immunochemotherapy (Exhibit Hall) -  Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2115;    
    During the next 7 months of follow-up, no recurrence or metastasis was found. Conclusions : Neoadjuvant therapy may have potential to simplify surgical treatment, which means down-stage to thoracic surgery, but benefit patients with the same oncology effect, negative margin, and better perioperative outcome.
  • ||||||||||  Tevimbra (tislelizumab-jsgr) / BeiGene
    Pathological Response to Neoadjuvant Tislelizumab Plus Chemotherapy in Potentially Resectable Stage IIIB NSCLC (Exhibit Hall) -  Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2008;    
    7%-89.4%) and 98.7% (95% CI, 92.79%-100.0%), respectively. Table 1: Efficacy results of included patients (N=75) Outcomes n/N (%, 95%CI) Tumor response CR 2/75 (0.03, 0.3-9.3) PR 59/75 (78.7, 67.7-87.3) SD 13/75 (17.3, 9.6-27.8) PD 1/75 (0.01, 0.03-7.2) ORR 61/75 (81.3, 70.7-89.4) DCR 74/75 (98.7, 92.8-100.0) Surgical resection Surgery rate 64/75 (85.3, 75.3-92.4) R0 64/64(100, 94.39-100) Pathologic outcomes pCR 28/64 (43.7, 32.4-56.7) MPR 47/64(73.4,60.91-83.7) Non-MPR 17/64 (26.6, 16.3-30.1) Tumor downstaging 54/64(84.37, 73.13-92.24) Conclusions : Tislelizumab in combination with chemotherapy as neoadjuvant therapy demonstrated promising antitumor activity for potentially resectable stage IIIB NSCLC with high rates of MPR and pCR.
  • ||||||||||  Kaitanni (cadonilimab) / Akesobio
    Perioperative Cadonilimab and Chemotherapy in Stage II-IIIA Non-Small-Cell Lung Cancer: Preliminary Results from a Phase II Study (Exhibit Hall) -  Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1934;    
    P2
    Methods : Participants with resectable stage II to IIIA NSCLC received platinum-based chemotherapy (nanoparticle albumin-bound paclitaxel 260mg/m 2 , carboplatin AUC 5) plus cadonilimab (10 mg/kg) administered intravenously every 3 weeks for 3 cycles before surgery, followed by adjuvant cadonilimab intravenously every 3 weeks for 9 cycles...Enrollment is ongoing, and extended follow-up is required to assess event-free survival accurately. (ClinicalTrials.gov number: NCT05377658.)